Trial reportInternational journal of women's health2025
Efficacy of a Mixed Wavelength Laser for Vaginal Health in Postmenopausal Women: A Randomized Controlled Trial.
Trial report in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical and vaginal microbiota effects of oral Lactobacillus crispatus M247 combined with vaginal laser therapy in menopausal women with atrophic vulvovaginitis: a prospective, randomized and controlled study.Lasers in medical science · 2026Trial
- Fractional COInternational urogynecology journal · 2026Review
- A Randomized Controlled Pilot Trial Evaluating the Efficacy of Intravaginal and Extravaginal K-Laser Therapy as a Personalized Non-Hormonal Treatment for Genitourinary Syndrome of Menopause.Journal of personalized medicine · 2026Article
- Advanced Fractional CO₂ Laser Treatment for Steroid-Induced Atrophy Scars: Clinical Outcomes.The American journal of case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients and Methods: A randomized single-blind sham-controlled trial was conducted. 31 postmenopausal women with Vaginal Maturation Value (VMV <50%) were randomized into laser or sham intervention groups, receiving three monthly treatments. VMV, vaginal pH, and GSM symptoms severity were measured at 3- and 9-months post-intervention, and AE were assessed. Results: 27 patients completed the study; 14 were randomly assigned to the laser and 13 to the sham group. At 3 months, VMV improved by 12.4% compared to the sham group (P= 0.033), indicating a significant reversal of VA and a significant patient global improvement (P=0.030). At 9 months, dyspareunia decreased significantly (P = 0.049), while other symptoms and patient satisfaction demonstrated a significant improvement trend. However, VMV in the laser group returned to baseline values. Vaginal pH remained unchanged. The laser intervention was well tolerated, with mild and self-limited AEs. Conclusion: The mixed wavelength laser enables a reduction of 10,600 nm laser power, enhancing its safety profile while achieving promising outcomes in GSM. It is a safe, well-tolerated, and effective alternative for GSM treatment when conventional therapies fail. Further studies with larger samples, varied settings, and extended follow-up are needed to assess its long-term efficacy and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.